Outset Medical Revenue and Competitors

Location

#4036

Growjo Ranking

Estimated Revenue & Valuation

  • Outset Medical's estimated annual revenue is currently $91.7M per year.(i)
  • Outset Medical received $132.0M in venture funding in August 2018.
  • Outset Medical's estimated revenue per employee is $108,264
  • Outset Medical's total funding is $458M.
  • Outset Medical's current valuation is $1.7B. (January 2022)

Employee Data

  • Outset Medical has 847 Employees.(i)
  • Outset Medical grew their employee count by 2% last year.

Outset Medical's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
SVP Operations and R&DReveal Email/Phone
3
SVP SalesReveal Email/Phone
4
VP Sales, Commercial DevelopmentReveal Email/Phone
5
Medical OfficerReveal Email/Phone
6
VP MarketingReveal Email/Phone
7
VP SalesReveal Email/Phone
8
General CounselReveal Email/Phone
9
VP Strategic InitiativesReveal Email/Phone
10
VP, Service & SupportReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Outset Medical?

Outset is a pioneering medical technology company that always puts the patient before the machine. Our human-centered model is designed to dramatically improve not only the care experience - for patients, families, providers and physicians alike - but also cost-efficiencies for providers. And to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization - along with hard work - is the surest path to invention. Because we believe a dialysis machine should be as easy to use as an everyday consumer product, Tablo was designed with simplicity in mind. One example is Tablo's touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. And with simplicity comes speed. We've set out to give people their time back. Tablo dramatically reduces the time involved in setting up and managing dialysis, whether at home or in clinic. There is simply less to do and less to learn.

keywords:Hardware,Healthcare,Medical Devices,Pharmaceuticals

$458M

Total Funding

847

Number of Employees

$91.7M

Revenue (est)

2%

Employee Growth %

$1.7B

Valuation

N/A

Accelerator

Outset Medical News

2022-04-17 - Outset Medical to Report First Quarter 2022 Financial Results on ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Apr 20, 2022--. Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a...

2022-04-13 - Zacks: Brokerages Expect Outset Medical, Inc. (NASDAQ:OM) to ...

Four analysts have provided estimates for Outset Medical's earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate...

2022-04-06 - Outset Medical Presents New Data on Home Dialysis at National ...

Outset Medical Presents New Data on Home Dialysis at National Kidney Foundation Spring Meetings. Findings Show Tablo® Hemodialysis System...

2020-02-10 - Outset Medical secures another $125M for its portable dialysis machine W h i t e p a p e r Weighing the Costs:

Outset Medical has raised $125 million to accelerate the U.S. commercialization of its all-in-one hemodialysis machine. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for an entire year? Enter the Agilent LabCentral Golden Ticket W ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$336.2M8559%$1.6M
#2
$171.4M856-10%$89.9M
#3
$176.2M868N/AN/A
#4
$250.6M8734%N/A
#5
$89M877-25%N/A

Outset Medical Funding

DateAmountRoundLead InvestorsReference
2015-06-10$91.0MUndisclosedFidelity Research and Management CompanyArticle
2017-05-04$76.5MUndisclosedT. Rowe Price Associates, IncArticle
2017-07-07$4.3MUndisclosedArticle
2018-08-29$132.0MDMubadala Investment CompanyArticle